FIELD: biotechnology.
SUBSTANCE: invention relates to the field of biotechnology. Nucleic acid molecules encoding chimeric antigen receptors (CAR) and expression vectors containing them are proposed. CARs include an extracellular domain that includes IL-13 or its variant that binds to interleukin-13Rα2 (IL13Rα2), a transmembrane region, a costimulating domain, and an intracellular signaling domain. A population of human T- cells expressing CAR targeted IL13Rα2. The human T- cell population contains central memory T- cells. In addition, the invention relates to a composition for the treatment of cancer containing the specified population of T- cells.
EFFECT: invention provides improved antitumor efficacy due to improved resistance of T- cells in the tumor micro environment.
10 cl, 27 dwg, 5 tbl, 12 ex
| Title | Year | Author | Number |
|---|---|---|---|
| CENTRAL MEMORY T-CELLS FOR ADOPTIVE T-CELL THERAPY | 2015 |
|
RU2763523C2 |
| INTRODUCTION OF CONSTRUCTED T CELLS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM CANCER | 2017 |
|
RU2757308C2 |
| CHIMERIC ANTIGEN RECEPTORS TARGETING HER2 | 2016 |
|
RU2753695C2 |
| CHIMERIC ANTIGEN RECEPTORS AIMED AT PSCA | 2016 |
|
RU2759879C2 |
| T-CELLS MODIFIED WITH A CHIMERIC ANTIGEN RECEPTOR TARGETING CS1 | 2015 |
|
RU2727451C2 |
| IL4/IL13 RECEPTOR MOLECULE FOR VETERINARY USE | 2018 |
|
RU2795591C2 |
| COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY AGAINST CD20 | 2017 |
|
RU2782699C2 |
| CHIMERIC ANTIGEN RECEPTORS TARGETING VARIANT III OF EPIDERMAL GROWTH FACTOR RECEPTOR | 2017 |
|
RU2751662C2 |
| INDUCIBLE CHIMERIC CYTOKINE RECEPTORS | 2019 |
|
RU2826155C2 |
| CELL | 2014 |
|
RU2717984C2 |
